Demethylation of CDKN2A in systemic lupus erythematosus and rheumatoid arthritis: a blood biomarker for diagnosis and assessment of disease activity

• Published in: Clinical rheumatology Vol. 42; no. 12; pp. 3387 - 3395
• Main Authors: Gravand, Abdollah, Alesaeidi, Samira, Khoshbakht, Shahrouz, Saghaei, Mozhdeh, Kenarangi, Taiebe, Mosallaei, Meysam, Soosanabadi, Mohsen
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2023; Springer Nature B.V
• Subjects: Adolescent; Arthritis, Rheumatoid; Autoimmune diseases; Biomarkers; Bisulfite; bisulfites; blood; Cyclin-Dependent Kinase Inhibitor p16 - metabolism; Demethylation; Diagnosis; Disease; DNA; DNA methylation; Endonuclease; Humans; Leukocytes (mononuclear); Leukocytes, Mononuclear - metabolism; Lupus; lupus erythematosus; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - genetics; Medicine; Medicine & Public Health; Original Article; pathogenesis; Peripheral blood mononuclear cells; phenotype; prognosis; Rheumatoid arthritis; Rheumatology; Statistical analysis; Systemic lupus erythematosus; Biomarker; Systemic lupus erythematosus; Methylation; Rheumatoid arthritis; CDKN2A
• ISSN: 0770-3198; 1434-9949; 1434-9949
• DOI: 10.1007/s10067-023-06736-z

   Introduction/objectives Considering the phenotypic and serological heterogeneity of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), significant challenges may intervene with the precise diagnosis. In this regard, numerous studies have shown that changes in DNA methylation levels can be used to distinguish between healthy individuals and those with SLE and RA, as well as to predict disease activity and prognosis. Methods In the current study, we evaluated quantitative methylation level of CDKN2A promoter in peripheral blood mononuclear cells (PBMCs) of SLE and RA patients, and healthy controls by methylation-quantification of endonuclease-resistant DNA (MethyQESD), a bisulfite conversion-independent method. Results Our findings revealed an excessive hypomethylation of CDKN2A in SLE and RA patients compared to healthy individuals ( P  <  0.001 ). Besides, by determining efficient cutoff value, the specificity of CDKN2A for correct diagnosis of healthy subjects was measured to be 77.30% and the sensitivity for SLE and RA diagnosis were 81.33%, and 72%, respectively. Furthermore, CDKN2A methylation level was shown to be positively associated with C3 and C4 levels and negatively associated with anti‑dsDNA concentration ( P  <  0.001 ). Moreover, a statistically significant difference in the DNA methylation levels of CDKN2A promoter was identified between SLE cases with age of ≤ 18 and patients with > 18 years of age ( P  = 0.025). Conclusion Our findings demonstrated that CDKN2A methylation levels in PBMCs of SLE and RA patients could be used as a promising diagnostic biomarker. The significant association between hypomethylation of CDKN2A promoter and disease activity factors in SLE patients, is suggesting that CDKN2A hypomethylation could be used as an alternative biomarker for assessment of disease activity. Key Points • Several studies have reported increased expression of CDKN2A in SLE and RA suggesting that it may be involved in the pathogenesis of these disorders. • CDKN2A hypomethylation has been implicated in different autoimmune diseases. • Our findings demonstrated that CDKN2A methylation levels in PBMCs of SLE and RA patients could be used as a promising diagnostic and prognostic biomarker.